Skip to content

Integrated Advancements in Neuroplasticity, Psychedelic Therapeutics, and AI-Driven Innovations for Precision Medicine.

Robert B. Kargbo

ACS Medicinal Chemistry Letters April 10, 2025 DOI: 10.1021/acsmedchemlett.5c00112 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Neuroplasticity
Key findings Innovations in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI platforms address challenges in neurological and psychiatric disorders, chronic pain, and computational accessibility.

Abstract

Recent advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms mark a new frontier in precision medicine. These innovations address critical challenges in neurological and psychiatric disorders, chronic pain management, and computational accessibility. By harnessing the principles of receptor modulation, targeted delivery systems, and simplified AI integration, these breakthroughs promise transformative solutions for patient care and technological development.